A
Alcista
Alcista · 25%NBIX
$166.71
Precio del escenario
$136.950
+1.055 (+0.77%)Al cierre
Loading chart…
- Máximo
- 138.230
- Apertura
- 137.260
- Precio medio ponderado por volumen
- 136.91
- Volumen
- 1.36M
- Capitalización
- 13.52B
- Mínimo
- 135.550
- Importe
- 186.19M
- EV/EBITDA, TTM
- 13.00
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
Análisis de IA of Neurocrine Biosciences, Inc (NBIX)
ComprarNeurocrine Biosciences Inc is a good buy right now due to its current price of $142.44, which is significantly below the average analyst price target of $221, suggesting a potential upside of 55%. Additionally, the forward P/E ratio of 14.12 indicates attractive valuation compared to its growth prospects. However, the main risk is the safety concerns surrounding the VYKAT XR acquisition, which has led to a 25% pullback in stock price since Q2.
Recomendaciones de analistas (13)
+31.20% de potencial alcista
Comprar
13 Comprar
0 Mantener
0 Vender
Actual: 136.95
Mínimo
143.00
Promedio
179.68
Máximo
203.00
BMO Capital
Market Perform
$150
2026-10-12
BMO Capital
2026-10-12
Precio objetivo
$150
Market Perform
Guggenheim
Comprar
$207
2026-10-05
Guggenheim
2026-10-05
Precio objetivo
$207
Comprar
UBS
Comprar
$214
2026-09-29
UBS
2026-09-29
Precio objetivo
$214
Comprar
Morgan Stanley
Equal Weight
$183
2026-09-11
Morgan Stanley
2026-09-11
Precio objetivo
$183
Equal Weight
Citi
Comprar
$253
2026-09-03
Citi
2026-09-03
Precio objetivo
$253
Comprar
Métricas de valoración
El PER previsto actual de Neurocrine Biosciences, Inc (NBIX) es 14.12, frente a su media de 5 años de 20.53.
Escenarios de precio de Alphio AI para NBIX
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con NBIX en cartera
Cronología de eventos
Noticias
1.010-12PRnewswireNeurocrine Biosciences Schedules Q3 2026 Earnings Call
8.509-30PRnewswireNeurocrine Advances Research on Prader-Willi Syndrome at FPWR Symposium
8.509-30NewsfilterNeurocrine Advances Research on Prader-Willi Syndrome with VYKAT XR Studies
5.009-29NASDAQ.COMNeurocrine Appoints New Chief Medical Officer
5.009-28PRnewswireNeurocrine Appoints New Chief Medical Officer
Preguntas frecuentes sobre NBIX, respondidas por Alphio AI
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Neurocrine Biosciences Inc is a good buy right now due to its current price of $142.44, which is significantly below the average analyst price target of $221, suggesting a potential upside of 55%. Additionally, the forward P/E ratio of 14.12 indicates attractive valuation compared to its growth prospects. However, the main risk is the safety concerns surrounding the VYKAT XR acquisition, which has led to a 25% pullback in stock price since Q2.
13 analysts cover NBIX: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 179.68.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.